Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 microbicide trial

Journal of Clinical Microbiology

Volumn 52, Issue 3, 2014, Pages 844-848

  Redd, Andrew D ^a,b   Mullis, Caroline E ^b   Wendel, Sarah K ^a   Sheward, Daniel ^c   Martens, Craig ^d   Bruno, Daniel ^d   Werner, Lise ^e   Garrett, Nigel J ^e   Abdool Karim, Quarraisha ^e   Williamson, Carolyn ^c   Porcella, Stephen F ^d   Quinn, Thomas C ^a,b   Abdool Karim, Salim S ^e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Research Technologies Branch   (United States)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

MICROBICIDE; PLACEBO; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; ENVELOPE GENE; ETHNIC GROUP; FEMALE; GEL; GROUP SPECIFIC ANTIGEN GENE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION RISK; KENYA; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; NONHUMAN; PATIENT ASSESSMENT; POPULATION RESEARCH; PRIMARY INFECTION; PRIORITY JOURNAL; SEROCONVERSION; SEXUAL INTERCOURSE; SOUTH AFRICA; SUPERINFECTION; VIRUS GENE; VIRUS LOAD; YOUNG ADULT;

ADENINE; ADULT; ANTI-INFECTIVE AGENTS; CHEMOPREVENTION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; KENYA; ORGANOPHOSPHONATES; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; SUPERINFECTION; VAGINAL CREAMS, FOAMS, AND JELLIES; VIRAL LOAD; YOUNG ADULT;

EID: 84894530260     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03143-13     Document Type: Article

References (16)

1. Redd AD, Collinson-Streng A, Martens C, Ricklefs S, Mullis CE, Manucci J, Tobian AA, Selig EJ, Laeyendecker O, Sewankambo N, Gray RH, Serwadda D, Wawer MJ, Porcella SF, Quinn TC. 2011. Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda using next generation deep sequencing. J. Clin. Microbiol. 49:2859-2867. http://dx.doi.org/10.1128/JCM.00804-11.
2. Redd AD, Mullis CE, Serwadda D, Kong X, Martens C, Ricklefs SM, Tobian AA, Xiao C, Grabowski MK, Nalugoda F, Kigozi G, Laeyendecker O, Kagaayi J, Sewankambo N, Gray RH, Porcella SF, Wawer MJ, Quinn TC. 2012. The rates of HIV superinfection and primary HIV incidence in a general population in Rakai, Uganda. J. Infect. Dis. 206:267-274. http://dx.doi.org/10.1093/infdis/jis325.
3. Redd AD, Quinn TC, Tobian AA. 2013. Frequency and implications of HIV superinfection. Lancet Infect. Dis. 3:622-628. http://dx.doi.org/10.1016/S1473- 3099(13)70066-5.
4. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Daar ES, Richman DD, Little SJ. 2004. Incidence of HIV superinfection following primary infection. JAMA 292:1177-1178. http://dx.doi.org/10.1001/jama.292.10.1177. (Pubitemid 39167405)
5. Wagner GA, Pacold ME, Kosakovsky Pond SL, Caballero G, Chaillon A, Rudolph AE, Morris SR, Little SJ, Richman DD, Smith DM. 22 November 2013. Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jit633.
6. Ronen K, McCoy CO, Matsen FA, Boyd DF, Emery S, Odem-Davis K, Jaoko W, Mandaliya K, McClelland RS, Richardson BA, Overbaugh J. 2013. HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog. 9:e1003593. http://dx.doi.org/10.1371/ journal.ppat.1003593.
7. Cortez V, Odem-Davis K, McClelland RS, Jaoko W, Overbaugh J. 2012. HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog. 8:e1002611. http://dx.doi.org/10.1371/journal.ppat. 1002611.
8. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O'Connor DH, Davis BT, Lee PK, Maier EL, Harlow J, Goulder PJ, Brander C, Rosenberg ES, Walker BD. 2002. HIV-1 superinfection despite broadCD8-T-cell responses containing replication of the primary virus. Nature 420:434-439. http://dx.doi.org/10.1038/nature01200. (Pubitemid 35415656)
9. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174. http://dx.doi.org/10.1126/science. 1193748.
10. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray CM, Abdool Karim Q, Grobler A, Barnabas N, Iriogbe I, Abdool Karim SS, Team CAIS. 2008. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 3:e1954. http://dx.doi.org/10.1371/journal.pone.0001954.
11. Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J. 2007. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog. 3:e177. http://dx.doi.org/10.1371/journal.ppat.0030177.
12. Piantadosi A, Ngayo MO, Chohan B, Overbaugh J. 2008. Examination of a second region of the HIV type 1 genome reveals additional cases of superinfection. AIDS Res. Hum. Retroviruses 24:1221. http://dx.doi.org/10.1089/ aid.2008.0100.
13. Gonzales MJ, Delwart E, Rhee SY, Tsui R, Zolopa AR, Taylor J, Shafer RW. 2003. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J. Infect. Dis. 188: 397-405. http://dx.doi.org/10.1086/376534. (Pubitemid 36960650)
14. Rachinger A, Manyenga P, Burger JA, Derks van de Ven TL, Stolte IG, Prins M, van 't Wout AB, Schuitemaker H. 2011. Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS. J. Infect. Dis. 203:1621-1628. http://dx.doi.org/10.1093/infdis/jir164.
15. Martin HL, Jr, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, Ndinya-Achola JO, Kreiss J. 1998. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 178:1053-1059. http://dx.doi.org/10.1086/515654. (Pubitemid 28452198)
16. Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS. 2011. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12:67. http://dx.doi.org/10.1186/1745-6215-12- 67.